{
  "id": 5167216,
  "title": "STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial",
  "url": "https://urgent.news/2026/09/02/stat-ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-02T20:37:24.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/"
  },
  "original_language": "en",
  "account": "Ultragenyx, a biotech firm, announced on Wednesday that its experimental treatment for Angelman syndrome, a rare disease causing severe intellectual disabilities and developmental delays, failed to demonstrate any advantage over a placebo in a large Phase 3 trial. The drug, called GTX-102, had previously shown promising results in earlier trials, sparking hope among families affected by the condition. Many advocates for patients with other neurological disorders also anticipated that GTX-102 could be the first of several medicines to enhance cognition, communication, and other aspects of life for those with intellectual disabilities. The news represents a substantial setback for Ultragenyx's business prospects, as the company primarily focuses on ultra-rare diseases for which it already holds multiple approved medications. Investors had placed significant hopes on the Angelman syndrome drug as Ultragenyx's route to financial success.",
  "summary": "Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.",
  "key_points": [
    "Ultragenyx's GTX-102 drug failed late-stage Angelman syndrome trial",
    "Phase 3 trial showed no advantage over placebo treatment",
    "Company's primary focus on ultra-rare diseases with approved meds"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}